Please assess the completion status of the following clinical trial:

Trial Title: RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria Patients with acute coronary syndromes with at least one additional risk factor for cardiovascular complications.~Exclusion criteria~1. Long term treatment with any other oral anticoagulant~2. Severe/disabling stroke within last 6 months~3. Conditions associated with increased bleeding risk~4. Anaemia or thrombocytopenia~5. Severe renal impairment~6. Liver disease~7. Positive pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran etexilate 50mg (Type: EXPERIMENTAL): twice daily dosing,
- Dabigatran etexilate 75mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 50mg bid
- Dabigatran etexilate 110mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 75mg bid
- dabigatran etexilate 150mg (Type: EXPERIMENTAL): twice daily dosing, patients with moderate renal impairment allocated 110mg bid
- placebo (Type: PLACEBO_COMPARATOR): matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).